Bcl‐2 and CD10 expression in the differential diagnosis of trichoblastoma, basal cell carcinoma, and basal cell carcinoma with follicular differentiation

Córdoba, Alicia; Gourichon, David; Larrinaga, B.; Iglesias, M.E.; Arrechea, M.A.; Yanguas, Juan Ignacio

doi:10.1111/j.1365-4632.2009.04076.x

Cited by 50 publications

(37 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The conservative treatment for TB is simple surgical resection, whereas, for BCC, free margins must be achieved, because it is a carcinoma and in general, its management differs because it is a malignant neoplasm. [4]…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemistry Panel for Differential Diagnosis of Basal Cell Carcinoma and Trichoblastoma

Memije

Luna²,

Almeida³

et al. 2014

Int J Trichol

View full text Add to dashboard Cite

Introduction:Basal cell carcinoma (BCC) is the most common malignant neoplasm in the skin and is considered to have a low degree of malignancy. BCC is invasive but rarely metastatic and originates in hair follicle-derived cells or interfollicular zones of the epidermis. Trichoblastoma (TB) is an infrequent benign skin neoplasm that differentiates toward follicular germinative cells. Both of these cutaneous lesions comprise nests of basaloid cells, and because the differential diagnosis is hard to obtain between them histologically due to their similarity, the correct diagnosis must be established.Materials and Methods:The sample size of this descriptive study consisted of 20 cases: 10 paraffin-embedded tissues that were diagnosed with carcinoma of solid basal cells with follicular differentiation and 10 TB tissues. The diagnosis of all samples was confirmed morphologically with hematoxylin and eosin. One-micron-thick sections were cut from each sample and analyzed semiquantitatively by immunohistochemistry (IHC). Differences in staining between BCC and TB were analyzed by Chi-square test.Results:Two of 10 TB cases were positive for Ki-67 versus 10 of 10 BCC samples. Cytokeratins 6 was expressed in 1 of 10 TB samples and in all BCC tissues. Staining with clone 34BE12 generated signals in all lesions at various intensities.Conclusion:The diagnosis between TBs and BCCs must be made histologically, because the treatment of BCC is radical and can compromise aesthetics and function, even for experienced pathologists. Because their morphological diagnosis is difficult, the histopathology results must be supported by an IHC panel.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunohistochemistry Panel for Differential Diagnosis of Basal Cell Carcinoma and Trichoblastoma

Memije

Luna²,

Almeida³

et al. 2014

Int J Trichol

View full text Add to dashboard Cite

show abstract

“…However, in the literature, diffuse Bcl-2 expression by basaliomatous cells was observed in basal cell carcinoma tumors, while expression of this marker only in the outermost layers of basaloid nests was observed in trichoepithelioma tumors; this difference in Bcl-2 localization was considered feasible for the discrimination between these two basaloid tumors. [15][16][17][18] Trichoepithelioma and basal cell carcinoma tumors displayed different epithelial membrane antigen staining patterns. However, epithelial membrane antigen expression did not reach significant 'Beta' values in the regression analysis.…”

mentioning

confidence: 99%

Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples

2012

View full text Add to dashboard Cite

Trichoepithelioma is a benign neoplasm that shares both clinical and histological features with basal cell carcinoma. It is important to distinguish these neoplasms because they require different clinical behavior and therapeutic planning. Many studies have addressed the use of immunohistochemistry to improve the differential diagnosis of these tumors. These studies present conflicting results when addressing the same markers, probably owing to the small number of basaloid tumors that comprised their studies, which generally did not exceed 50 cases. We built a tissue microarray with 162 trichoepithelioma and 328 basal cell carcinoma biopsies and tested a panel of immune markers composed of CD34, CD10, epithelial membrane antigen, Bcl-2, cytokeratins 15 and 20 and D2-40. The results were analyzed using multiple linear and logistic regression models. This analysis revealed a model that could differentiate trichoepithelioma from basal cell carcinoma in 36% of the cases. The panel of immunohistochemical markers required to differentiate between these tumors was composed of CD10, cytokeratin 15, cytokeratin 20 and D2-40. The results obtained in this work were generated from a large number of biopsies and resulted in the confirmation of overlapping epithelial and stromal immunohistochemical profiles from these basaloid tumors. The results also corroborate the point of view that trichoepithelioma and basal cell carcinoma tumors represent two different points in the differentiation of a single cell type. Despite the use of panels of immune markers, histopathological criteria associated with clinical data certainly remain the best guideline for the differential diagnosis of trichoepithelioma and basal cell carcinoma.

show abstract

“…We surmised that epidermal stem cells might transdifferentiate into hEMSCPCs in the microenvironment supplied by the special medium. To investigate this possibility and to examine phenotypic changes during long-term culture, we examined the expression of several markers known to be expressed by skin-derived cells, including the MSC markers CD73, CD90, and CD105, the fibroblast marker vimentin, the NSC marker nestin, the neuronal marker β-III tubulin, the glial marker GFAP, the immunocyte markers CD3, CD19, CD16, and CD45, the HSC marker CD34, the epithelial cell marker CK19, the basilar membrane cell marker CD1036, the vascular endothelial cell markers CD31 and VEGF-R2, and the human histocompatibility antigens HLA-DR and HLA-I. We assessed expression patterns at passages 2, 10, 20, and 30 by immunohistochemisty.…”

Section: Resultsmentioning

confidence: 99%

Generation of Human Epidermis-Derived Mesenchymal Stem Cell-like Pluripotent Cells (hEMSCPCs)

Huang

et al. 2013

Sci Rep

View full text Add to dashboard Cite

We isolated human epidermis-derived mesenchymal stem cell-like pluripotent cells (hEMSCPCs) and demonstrate efficient harvesting, maintenance in vitro for at least 30 passages, reprogramming into multiple phenotypes in vivo, and integration into adult host tissues after injection into the mouse blastocyst to create chimeras. Cell phenotype was examined by karyotyping, immunostaining, immunofluorescence, and flow cytometry. A nested PCR protocol using primers specific for human SRY genes was designed to detect hEMSCPC-derived cells in female chimeric mice. FISH was used to validate the results of nested PCR. Results indicated that hEMSCPCs were derived from epidermis but were distinct from epidermal cells; they resembled mesenchymal stem cells (MSCs) morphologically and expressed the main markers of MSCs. About half of all female offspring of mice implanted with embryos injected with hEMSCPCs at the blastocyst stage harbored the human Y chromosome and tissue-specific human protein, thereby demonstrating the transdifferentiation of hEMSCPCs.

show abstract

Bcl‐2 and CD10 expression in the differential diagnosis of trichoblastoma, basal cell carcinoma, and basal cell carcinoma with follicular differentiation

Abstract: CD10 is useful for distinguishing between BCC with widespread follicular differentiation and trichoblastomas.

Cited by 50 publications

References 13 publications

Immunohistochemistry Panel for Differential Diagnosis of Basal Cell Carcinoma and Trichoblastoma

Immunohistochemistry Panel for Differential Diagnosis of Basal Cell Carcinoma and Trichoblastoma

Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples

Generation of Human Epidermis-Derived Mesenchymal Stem Cell-like Pluripotent Cells (hEMSCPCs)

Contact Info

Product

Resources

About